Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 8281-8290 of 11534

Edit search filters
  1. Establishing The Validity, Responsiveness, And Appropriateness Of Patient-Reported Outcome Measures For Adult Traumatic BPI

    Rochester, MN

  2. A Study Of Philips Camera Vital Signs #2

    Rochester, MN

  3. Arthroscopic Treatment of Scapholunate Instability

    Rochester, MN

  4. VCRC Longitudinal Study Of Central Nervous System Vasculitis (CNSV)

    Rochester, MN

  5. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. A Study Of Intraoperative Neurophysiologic Biomarkers Of Spinal Cord Stimulator Lead Placement

    Rochester, MN

  7. Patient Comfort with Dermatology Resident in Cosmetic Procedures

    Scottsdale/Phoenix, AZ

  8. An Observational Study In Children And Adults With Stargardt Disease

    Rochester, MN

  9. A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

    Rochester, MN

  10. A Study Of Biomarkers Of Immune Checkpoint Inhibitors-Associated Nephrotoxicity

    Rochester, MN

.

Mayo Clinic Footer